Pain management companies' shares are trading down an average of 24 percent due to increased competition, according to a Seeking Alpha report.
Pain management companies, such as Acura Pharmaceuticals, Endo Pharmaceuticals and Pacira Pharmaceuticals, are facing increased competition from generic drugs and patent expirations. The patents for Lyrica an anticonvulsant, and Cymbalta, an antidepressant, will expire soon. Generic pharmaceutical companies are developing more generic medications like Teva Pharmaceuticals and its development of Fentora, a generic drug for breakthrough pain with fentanyl.
Related Articles on Pain Management:
Fibronectin Injection After Spinal Cord Injury Can Relieve Pain
Market for Chronic Pain Therapies $20B Through 2020
CVS to Stop Filling Some Prescriptions for Painkillers in Florida
Pain management companies, such as Acura Pharmaceuticals, Endo Pharmaceuticals and Pacira Pharmaceuticals, are facing increased competition from generic drugs and patent expirations. The patents for Lyrica an anticonvulsant, and Cymbalta, an antidepressant, will expire soon. Generic pharmaceutical companies are developing more generic medications like Teva Pharmaceuticals and its development of Fentora, a generic drug for breakthrough pain with fentanyl.
Related Articles on Pain Management:
Fibronectin Injection After Spinal Cord Injury Can Relieve Pain
Market for Chronic Pain Therapies $20B Through 2020
CVS to Stop Filling Some Prescriptions for Painkillers in Florida